Drug Development: Latest Strategies to Fast-Track Innovation
The conventional drug development pipeline—from target discovery through clinical trials to regulatory approval—traditionally spans more than a decade and costs billions of dollars.
September 28, 2025
by Sadia Ajmal
From Molecule to Market: Innovations Accelerating the Future of Drug Development
Drug discovery and development has historically been a lengthy, high risk, and costly process, often spanning more than a decade and consuming billions of dollars before a product reaches patients.
September 4, 2025
by Annie Roys
Strategies to Facilitating Accelerated Drug Development
The article details FDA's Accelerated Drug Development, including guidelines, definition of serious conditions, strategies, features, and withdrawal reasons.
February 17, 2025
by Muhammad Asim Niazi
How to Choose a Small-molecule Drug Substance Partner
In this article, we will specifically focus on criteria for selecting a small-molecule drug substance partner.
August 2, 2024
by Saher Haider
New Drugs for Old: Repurposing and Repositioning Pharmaceuticals
Drug repurposing and repositioning offers a cost effective and efficient route to the market that allows patients to get access to drugs more quickly.
July 15, 2024
by Suzanne Elvidge
Vetter Wins Best Managed Companies Award 2024
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.
May 30, 2024
by PharmaSources
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents.
March 27, 2024
by PharmaSources
How could AI change drug development by ChatGPT
Artificial Intelligence (AI) has the potential to significantly impact and revolutionize the field of drug development in several ways.
February 26, 2024
by PharmaSources
Overview of New "Don't Eat Me" Target CD24 Research
Recently, Antengene Corporation announced that the Phase I clinical trial application (IND) of its global first anti-CD24 monoclonal antibody, ATG-031, had been approved by FDA.
July 3, 2023
by Zhaoruijie/PharmaSources
Simplifying AI Data Analysis for Scientists – as REPROCELL, IBM and STFC Hartree Centre Successfully Launch Pharmacology-AI Platform
On June 1,2023,REPROCELL announces the launch of a new commercial service, Pharmacology-AI.
June 5, 2023
by PharmaSources
ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT - A Shortcut to Successful Lentivirus Manufacturing
May 17, 2023,ProBioGen announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT as a new platinum standard for LV production at this year's PEGS Boston 2023.
May 18, 2023
by PharmaSources
SeraNovo and AstraZeneca to Collaborate on Research Projects
SeraNovo is pleased to announce the closing of a multi-compound deal with AstraZeneca.SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi-compound deal with AstraZeneca.
May 16, 2023
by PharmaSources